Literature DB >> 19539703

Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration.

Ai Kadokura1, Tsuneo Yamazaki, Satoko Kakuda, Kouki Makioka, Cynthia A Lemere, Yukio Fujita, Masamitsu Takatama, Koichi Okamoto.   

Abstract

TAR-DNA-binding protein 43 (TDP-43) was considered to be a disease-specific component of ubiquitin-positive and tau-negative inclusions in the brains of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis (ALS). However, this protein also accumulates abnormally in neurons in other neurodegenerative diseases, including Alzheimer's disease (AD). Although the role of TDP-43 deposition in these diseases is not clear, abnormal phosphorylation of the protein is suggested to be a critical step in disease pathogenesis. In this study, we generated a new phosphorylation-dependent TDP-43 antibody and examined AD brain sections from temporal lobes, including the hippocampus and temporal neocortex, by immunohistochemistry. The antibody, called A2, specifically recognized phosphorylated TDP-43 in western blotting using ALS and AD specimens, detecting a strong 45kDa band and several shorter fragments at around 25kDa with smears. Immunohistochemistry demonstrated neuronal cytoplasmic inclusions in AD brain sections without staining nuclei that were normal physiological TDP-43 localization sites. These results were consistent with previous reports. However, intraneuronal dot-like structures were also intensely labeled by immunohistochemistry. These structures were observed in all the AD brain sections examined and also occurred in sections from the brains of aged subjects without AD pathologies. The morphological and immunohistochemical characteristics of these granular structures were compatible with those of granulovacuolar degeneration (GVD). The A2 antibody clearly and intensely detected granular structures distributed over the hippocampus, subiculum, parahippocampus and temporal neocortex. Thus, immunohistochemistry using phosphorylation-dependent TDP-43 antibodies would be a new useful tool for identifying GVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539703     DOI: 10.1016/j.neulet.2009.06.024

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

Review 1.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

2.  Granulovacuolar degeneration (GVD) bodies of Alzheimer's disease (AD) resemble late-stage autophagic organelles.

Authors:  K E Funk; R E Mrak; J Kuret
Journal:  Neuropathol Appl Neurobiol       Date:  2011-04       Impact factor: 8.090

3.  Pathology of clinical and preclinical Alzheimer's disease.

Authors:  Dietmar Rudolf Thal; Christine von Arnim; W Sue T Griffin; Haruyasu Yamaguchi; Robert E Mrak; Johannes Attems; Ajeet Rijal Upadhaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

4.  Granulovacuolar degenerations appear in relation to hippocampal phosphorylated tau accumulation in various neurodegenerative disorders.

Authors:  Yuu Yamazaki; Tomoyasu Matsubara; Tetsuya Takahashi; Takashi Kurashige; Eisuke Dohi; Masanori Hiji; Yoshito Nagano; Takemori Yamawaki; Masayasu Matsumoto
Journal:  PLoS One       Date:  2011-11-03       Impact factor: 3.240

5.  Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles.

Authors:  Sally Hunter; Thais Minett; Tuomo Polvikoski; Elizabeta Mukaetova-Ladinska; Carol Brayne
Journal:  Alzheimers Res Ther       Date:  2015-08-28       Impact factor: 6.982

6.  Molecular markers for granulovacuolar degeneration are present in rimmed vacuoles.

Authors:  Masahiro Nakamori; Tetsuya Takahashi; Tomokazu Nishikawa; Yu Yamazaki; Takashi Kurashige; Hirofumi Maruyama; Koji Arihiro; Masayasu Matsumoto
Journal:  PLoS One       Date:  2013-11-28       Impact factor: 3.240

7.  Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43.

Authors:  Rachel H Tan; Claire E Shepherd; Jillian J Kril; Heather McCann; Andrew McGeachie; Ciara McGinley; Andrew Affleck; Glenda M Halliday
Journal:  Acta Neuropathol Commun       Date:  2013-07-10       Impact factor: 7.801

8.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease.

Authors:  Jeong-Sun Ju; Rodrigo A Fuentealba; Sara E Miller; Erin Jackson; David Piwnica-Worms; Robert H Baloh; Conrad C Weihl
Journal:  J Cell Biol       Date:  2009-12-14       Impact factor: 10.539

9.  Phosphatidylinositol-4,5-bisphosphate is enriched in granulovacuolar degeneration bodies and neurofibrillary tangles.

Authors:  Tomokazu Nishikawa; Tetsuya Takahashi; Masahiro Nakamori; Yu Yamazaki; Takashi Kurashige; Yoshito Nagano; Yoshihiko Nishida; Yuishin Izumi; Masayasu Matsumoto
Journal:  Neuropathol Appl Neurobiol       Date:  2014-06       Impact factor: 8.090

10.  Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.

Authors:  Mercedes Prudencio; Jack Humphrey; Sarah Pickles; Anna-Leigh Brown; Sarah E Hill; Jennifer M Kachergus; J Shi; Michael G Heckman; Matthew R Spiegel; Casey Cook; Yuping Song; Mei Yue; Lillian M Daughrity; Yari Carlomagno; Karen Jansen-West; Cristhoper Fernandez de Castro; Michael DeTure; Shunsuke Koga; Ying-Chih Wang; Prasanth Sivakumar; Cristian Bodo; Ana Candalija; Kevin Talbot; Bhuvaneish T Selvaraj; Karen Burr; Siddharthan Chandran; Jia Newcombe; Tammaryn Lashley; Isabel Hubbard; Demetra Catalano; Duyang Kim; Nadia Propp; Samantha Fennessey; Delphine Fagegaltier; Hemali Phatnani; Maria Secrier; Elizabeth Mc Fisher; Björn Oskarsson; Marka van Blitterswijk; Rosa Rademakers; Neil R Graff-Radford; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs; E Aubrey Thompson; Towfique Raj; Michael Ward; Dennis W Dickson; Tania F Gendron; Pietro Fratta; Leonard Petrucelli
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.